Featured Research

from universities, journals, and other organizations

Gene Therapy: Identifying Where Genes Can Successfully Integrate

Date:
August 6, 2007
Source:
Journal of Clinical Investigation
Summary:
Gene therapy -- whereby a retrovirus that integrates into the genome of a treated patient is used to deliver the gene of interest -- has been used to treat some individuals with inherited diseases such as X-linked SCID, a disease that causes widespread immunosuppression and therefore susceptibility to infection. However, a small number of the treated individuals developed leukemia-like diseases because the retrovirus integrated into the genome at a site(s) that caused the cells to divide uncontrollably.

Gene therapy -- whereby a retrovirus that integrates into the genome of a treated patient is used to deliver the gene of interest -- has been used to treat some individuals with inherited diseases such as X-linked SCID, a disease that causes widespread immunosuppression and therefore susceptibility to infection.

However, a small number of the treated individuals developed leukemia-like diseases because the retrovirus integrated into the genome at a site(s) that caused the cells to divide uncontrollably.

Analysis of the sites of retroviral integration in individuals treated with gene therapy is therefore of utmost importance to the further development of such gene therapy approaches and three studies that appear in the August issue of the Journal of Clinical Investigation address this issue.

The three studies -- reported by researchers from the National Center for Tumor Diseases, Heidelberg, Germany; University College London, London, United Kingdom; and the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy -- indicate that the retroviruses used to deliver the genes of interest in these studies, gammaretroviruses, integrated near the 5" ends of genes that are active in the treated cell population.

Although the diversity of the detected retroviral integration sites decreased following transplantation into patients because the treated cells differentiated, the sites detected remained at the 5" end of genes active in the cell populations analyzed. Importantly, the retrovirus integration sites observed in cells from successfully treated patients were not significantly different from those observed in cells from patients that went on to develop leukemia-like disease.

As discussed in the accompanying commentary by Frederic Bushman from the University of Pennsylvania, Philadelphia, these studies are critical if researchers are to determine whether the dangers of retroviral gene therapy can be predicted and/or eliminated.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Gene Therapy: Identifying Where Genes Can Successfully Integrate." ScienceDaily. ScienceDaily, 6 August 2007. <www.sciencedaily.com/releases/2007/08/070802211036.htm>.
Journal of Clinical Investigation. (2007, August 6). Gene Therapy: Identifying Where Genes Can Successfully Integrate. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/08/070802211036.htm
Journal of Clinical Investigation. "Gene Therapy: Identifying Where Genes Can Successfully Integrate." ScienceDaily. www.sciencedaily.com/releases/2007/08/070802211036.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins